Basilea Pharmaceutica AG provided earnings guidance for the year 2021. Total revenue, including revenue contributions from Cresemba and Zevtera as well as BARDA reimbursements, offsetting ceftobiprole phase 3 development expenses and other revenue contributions, is expected to amount to approximately CHF 148 million (fiscal year 2020: CHF 127.6 million).